Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques

Drug Metabolism and Disposition

Volumn 32, Issue 11, 2004, Pages 1218-1229

  Afzelius, Lovisa ^a,b,e   Raubacher, Florian ^a   Karlén, Anders ^b   Jørgensen, Flemming Steen ^e   Andersson, Tommy B ^a   Masimirembwa, Collen M ^a   Zamora, Ismael ^c,d  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Lead Molecular Design   (Spain)

^d INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYTOCHROME P450 2C5; CYTOCHROME P450 2C9; CYTOCHROME P450 ISOENZYME; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS;

EID: 6944226372     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.11.1218     Document Type: Article

References (38)

1. Afzelius L, Zamora I, Ridderstrom M, Andersson TB, Karlen A, and Masimirembwa CM (2001) Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol 59: 909-919.
2. Baroni M, Cruciani G, Costantino G, Riganelli D, Valigi R, and Clementi S (1993) Generating optimal linear PLS estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems. Quant Struct-Act Relat 12:9-20.
3. Berendsen HJ, Postma JPM, van Gunsteren WF, DiNola A, and Haak JR (1984) Molecular dynamics with coupling to an external bath. J Phys Chem 81:3684-3690.
4. Case DA, Pearlman DA, Caldwell JW, Cheatham TE III, Wang J, Ross WS, Simmerling CL, Darden TA, Merz KM, Stanton RV, et al. (2002) AMBER 7, University of California, San Francisco.
5. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM Jr, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, and Kollman PA (1995) A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J Am Chem Soc 117:5179-5197.
6. Cupp-Vickery J, Anderson R, and Hatziris Z (2000) Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proc Natl Acad Sci USA 97:3050-3055.
7. Dai R, Pincus MR, and Friedman FK (2000) Molecular modeling of mammalian cytochrome P450. Cell Mol Life Sci 57:487-499.
8. Davies C, Witham K, Scott JR, Pearson A, DeVoss JJ, Graham SE, and Gillam EMJ (2004) Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9). Drug Metab Dispos 32:431-436.
9. de Groot MJ, Alex AA, and Jones BC (2002) Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J Med Chem 45:1983-1993.
10. Flanagan JU, McLaughlin LA, Paine MJ, Sutcliffe MJ, Roberts GC, and Wolf CR (2003) Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity. Biochem J 370:921-926.
11. Giammona DA (1984), Ph.D. thesis, University of California.
12. Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849-857.
13. Graham-Lorence S and Peterson JA (1996) P450s: structural similarities and functional differences. FASEB J 10:206-214.
14. Hasemann CA, Ravichandran KG, Peterson JA, and Deisenhofer J (1994) Crystal structure and refinement of cytochrome P450terp at 2.3 A resolution. J Mol Biol 236:1169-1185.
15. Jung F, Griffin KJ, Song W, Richardson TH, Yang M, and Johnson EF (1998) Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. Biochemistry 37:16270-16279.
16. Kastenholz MA, Pastor M, Cruciani G, Haaksma EE, and Fox T (2000) GRID/CPCA: a new computational tool to design selective ligands. J Med Chem 43:3033-3044.
17. Kirton SB, Baxter CA, and Sutcliffe MJ (2002) Comparative modelling of cytochromes P450. Adv Drug Delivery Rev 54:385-406.
18. Laskowski RA, MacArthur MW, Moss DS, and Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Ctystallogr 26:283-291.
19. Lewis DF (2000) Modeling human cytochromes P450 for evaluating drug metabolism: an update. Drug Metab Drug Interact 16:307-324.
20. Lewis DF (2002) Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 32:305-323.
21. Lewis DF, Dickins M, Weaver RJ, Eddershaw PJ, Goldfarb PS, and Tarbit MH (1998) Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica 28:235-268.
22. Melet A, Assrir N, Jean P, Pilar Lopez-Garcia M, Marques-Soares C, Jaouen M, Dansette PM, Sari MA, and Mansuy D (2003) Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365 and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys 409:80-91.
23. Ortiz de Montellano PR and De Voss JJ (2002) Oxidizing species in the mechanism of cytochrome P450. Nat Prod Rep 19:477-493.
24. Payne VA, Chang Y-T, and Loew GH (1999) Homology modeling and substrate binding study of human CYP2C9 enzyme. Proteins Struct Funct Genet 37:176-190.
25. Peterson JA and Graham SE (1998) A close family resemblance: the importance of structure in understanding cytochromes P450. Structure 6:1079-1085.
26. Poulos TL, Finzel BC, and Howard AJ (1986) Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. Biochemistry 25:5314-5322.
27. Riddersrrom M, Masimirembwa C, Trump-Kallmeyer S, Ahlefelt M, Otter C, and Andersson TB (2000) Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem Biophys Res Commun 270:983-987.
28. Ridderstrom M, Zamora I, Fjellstrom O, and Andersson TB (2001 ) Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18 and 2C19 homology models using GRID/CPCA. J Med Chem 44:4072-4081.
29. Ryckaert J-R, Ciccotti G, and Berendsen HJC (1977) Numerical integration of the cartesian equation of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23:1977.
30. Schlichting I, Berendzen J, Chu K, Stock AM, Maves SA, Benson DE, Sweet RM, Ringe D, Petsko GA, and Sugar SG (2000) The catalytic pathway of cytochrome p450cam at atomic resolution. Science (Wash DC) 287:1615-1622.
31. Sevrioukova IF, Li H, Zhang H, Peterson JA, and Poulos TL (1999) Structure of a cytochrome P450-redox partner electron-transfer complex. Proc Natl Acad Sci USA 96:1863-1868.
32. Szklarz GD and Halpert JR (1997) Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. Life Sci 61:2507-2520.
33. Wester MR, Johnson EF, Marques-Soares C, Dansette PM, Mansuy D, and Stout CD (2003a) Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution: evidence for multiple substrate binding modes. Biochemistry 42:6370-6379.
34. Wester MR, Johnson EF, Marques-Soares C, Dijols S, Dansette PM, Mansuy D, and Stout CD (2003b) Structure of mammalian cytochrome P450 2C5 complexed with diciofenac at 2.1 Å resolution: evidence for an induced fit model of substrate binding. Biochemistry 42:9335-9345.
35. Williams PA, Cosme J, Sridhar V, Johnson EF, and McRee DE (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5:121-131.
36. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature (Lond) 424:464-468.
37. Word J, Lovell SC, Richardson JS, and Richardson DC (1999) Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol 285:1733-1747.
38. Zamora I, Afzelius L, and Cruciani G (2003) Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. J Med Chem 46:2313-2324.